GlassScriptPhysician profile
Shaoming Huang
NPI 1770583486
$3,935.87
in general payments reported to CMS, 2019-2025
35 companies · $1,170 in 2025
The $1,170 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $202 · 2021: $273 · 2022: $343 · 2023: $644 · 2024: $1,046 · 2025: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,859.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $572.81 | 2021-2025 | |
| Amgen INC. | $384.12 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $360.03 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $277.95 | 2019-2025 | Farxiga |
| Vifor Pharma, INC. | $243.37 | 2021-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $220.43 | 2019-2025 | Velphoro |
| Novartis Pharmaceuticals Corporation | $212.28 | 2024-2025 | |
| Horizon Therapeutics Plc | $211.33 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $201.08 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $174.14 | 2020-2025 | Terlivaz |
| Travere Therapeutics, INC. | $115.99 | 2022-2025 | |
| Genzyme Corporation | $103.52 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.22 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $89.67 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $82.83 | 2024-2025 | Ibsrela |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $60.53 | 2019-2024 | Injectafer |
| Akebia Therapeutics INC | $57.92 | 2019-2020 | |
| Scpharmaceuticals INC. | $52.58 | 2024-2025 | |
| Veloxis Pharmaceuticals, INC. | $48.78 | 2024-2025 | Envarsus |
| Cycle Pharmaceuticals INC | $44.69 | 2025 | Venxxiva |
| Alnylam Pharmaceuticals INC. | $28.56 | 2021-2023 | Oxlumo |
| Mallinckrodt Enterprises LLC | $27.76 | 2019 | |
| Glaxosmithkline, LLC. | $27.64 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $27.47 | 2024 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $26.76 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.10 | 2019-2020 | |
| Renalytix Ai, INC. | $24.75 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Outset Medical INC | $23.04 | 2023 | |
| Nxstage Medical, INC. | $19.64 | 2025 | Liberty Select Cycler, Pureflow Sl, Nxstage System One |
| Kyowa Kirin, INC. | $19.32 | 2025 | |
| Medtronic, INC. | $15.49 | 2024 | Symplicity G3 |
| Merck Sharp & Dohme LLC | $15.32 | 2025 | Prevymis |
| Lundbeck LLC | $14.95 | 2020 | |
| Novo Nordisk INC | $13.93 | 2023 | Ozempic |
| Opko Pharmaceuticals, LLC | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaoming Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.